Means Investment CO. Inc. Purchases 194 Shares of Eli Lilly and Company $LLY

Means Investment CO. Inc. increased its position in Eli Lilly and Company (NYSE:LLY) by 4.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,021 shares of the company’s stock after acquiring an additional 194 shares during the period. Means Investment CO. Inc.’s holdings in Eli Lilly and Company were worth $3,914,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the company. PNC Financial Services Group Inc. grew its stake in shares of Eli Lilly and Company by 97.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock valued at $83,669,349,000 after purchasing an additional 50,002,551 shares during the period. Nuveen LLC bought a new stake in Eli Lilly and Company during the first quarter valued at approximately $4,613,912,000. Vanguard Group Inc. grew its position in Eli Lilly and Company by 6.7% during the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock valued at $65,432,218,000 after buying an additional 4,975,395 shares during the period. Cohen Investment Advisors LLC grew its position in Eli Lilly and Company by 7,975.5% during the first quarter. Cohen Investment Advisors LLC now owns 783,651 shares of the company’s stock valued at $647,225,000 after buying an additional 773,947 shares during the period. Finally, Assenagon Asset Management S.A. grew its position in Eli Lilly and Company by 106.8% during the second quarter. Assenagon Asset Management S.A. now owns 1,481,031 shares of the company’s stock valued at $1,154,508,000 after buying an additional 765,010 shares during the period. Institutional investors own 82.53% of the company’s stock.

Insiders Place Their Bets

In related news, CEO David A. Ricks bought 1,632 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the transaction, the chief executive officer owned 546,601 shares in the company, valued at $352,431,926.77. The trade was a 0.30% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Gabrielle Sulzberger acquired 117 shares of the company’s stock in a transaction on Tuesday, August 12th. The shares were bought at an average cost of $641.18 per share, with a total value of $75,018.06. Following the acquisition, the director directly owned 2,703 shares in the company, valued at approximately $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased a total of 4,514 shares of company stock worth $2,894,841 over the last ninety days. 0.13% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on LLY. Hsbc Global Res raised shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 27th. Leerink Partners reissued a “market perform” rating and set a $715.00 price target on shares of Eli Lilly and Company in a report on Thursday, August 7th. Berenberg Bank reissued a “hold” rating and set a $830.00 price target (down previously from $970.00) on shares of Eli Lilly and Company in a report on Wednesday, September 17th. Leerink Partnrs lowered Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 7th. Finally, HSBC boosted their price objective on Eli Lilly and Company from $700.00 to $800.00 in a research note on Wednesday, October 1st. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $948.56.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $833.08 on Friday. The firm has a market cap of $788.47 billion, a price-to-earnings ratio of 54.45, a price-to-earnings-growth ratio of 1.16 and a beta of 0.47. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The business has a 50-day moving average price of $742.42 and a 200-day moving average price of $765.94. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $937.00.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. The firm had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business’s quarterly revenue was up 37.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.